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Results
The tumour size analysis identiﬁed four cutpoints at 2, 3, 5 and 7 cm. 
These generated ﬁve tumour size subgroups (2 cm or less; over 2 cm to 
3 cm ; over 3 cm to 5 cm ; over 5 cm to 7 cm; and over 7 cm in largest 
dimension) with statistically signiﬁcant survival differences. Five-
year survival for patients with pT1-T2N0M0R0 tumours according 
to these ﬁve tumour size subgroups was: 77%, 71%, 58%, 49%, and 
35%, respectively (p < 0.0001). The same prognostic degradation was 
found when tumours with any N and any type of resection (complete 
and incomplete) were analysed. Pathologic T2-anyN tumours greater 
than 7 cm in largest dimension were found to have similar prognosis to 
pT3-anyN tumours, with 5-year survival of 35% and 38%, respectively 
(p = 0.2739). The same degradation of survival was found when clini-
cal tumour size was analysed, but there were no statistically signiﬁcant 
differences in the ﬁrst three smaller size groups. Clinical T2N0 tumours 
greater than 7 cm and cT3N0 tumours had similar prognosis, too, with 
5-year survival rates of 26% and 29%, respectively (p = 0.6111). 
Pathologic T4N0-anyR tumours so classiﬁed by the presence of ad-
ditional nodule(s) in the same lobe had the same prognosis as pT3N0-
anyR tumours, with 5-year survival rates of 45% and 38%, respectively 
(p = 0.3685). 
Pathologic M1 (N0 R0) tumours so classiﬁed by additional nodule(s) in 
another ipsilateral lobe had similar prognosis to pT4 tumours by other 
descriptors other than additional nodule(s). Their 5-year survival rates 
were 48% and 35%, respectively (p = 0.1090).
Patients with cT4N0 tumours by pleural dissemination (pleural effusion 
or pleural nodules) had signiﬁcantly worse prognosis than patients with 
cT4N0 tumours by other descriptors. Five-year survival rates were 2% 
and 25%, respectively (p = 0.0001). Survival of patients with cT4N0 
tumours by pleural dissemination was similar to that of patients with 
M1 tumours.
All these results were internally and externally validated.
Conclusions
Based on the results of this study, the following changes in the next edi-
tion of the TNM classiﬁcation for lung cancer can be recommended: 
1) T1 tumours could be subclassiﬁed as T1a (2 cm or less) or T1b (over 
2 cm to 3 cm); 
2) T2 tumours could be subclassiﬁed as T2a (over 3 cm to 5 cm, or T2 
by other descriptor and 5 cm or less in largest dimension) or T2b 
(over 5 cm to 7 cm); 
3) T2 tumours over 7 cm in largest dimension could be reclassiﬁed as 
T3; 
4) T4 tumours by additional nodule(s) in the same lobe could be reclas-
siﬁed as T3; 
5) M1 tumours by additional nodule(s) in a different ipsilateral lobe 
could be reclassiﬁed as T4; and 
6) pleural dissemination (malignant pleural and pericardial effusions 
and pleural nodules) could be reclassiﬁed as M1. 
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Accurate staging of lymph node involvement is a critical aspect of 
the initial management of patients with non-metastatic non-small cell 
lung cancer (NSCLC) that inﬂuences decisions about the appropriate-
ness and timing of surgery, radiation and systemic therapy. Since the 
lung cancer staging system was ﬁrst developed in 19731, lymph node 
involvement has been categorized as N0 (no nodes involved), N1 
(peribronchial, interlobar or perihiar lymph nodes involved) N2 (ipsi-
lateral mediastinal nodes involved), or N3 (contralateral mediastinal or 
supraclavicular nodes involved). 
During the past 20 years, numerous studies have evaluated the validity 
of the N descriptors and have suggested that these could be reﬁned to 
provide more accurate prognostic stratiﬁcation by subdividing them 
either according to speciﬁc anatomical locations (e.g. N1 peribronchial 
versus N1 perihilar) or the number of involved lymph nodes (e.g. single 
versus multiple N2 nodes). This study was undertaken as part of the 
effort by the staging committee of the International Association for the 
Study of Lung Cancer (IASLC) to determine if the current international 
lung cancer staging system required revision in preparation for the 7th 
edition of the UICC (Union Internationale Contre le Cancer) and AJCC 
(American Joint Commission on Cancer) cancer staging manuals.
The database was developed through an international consortium 
of institutions and clinical trials groups that submitted staging and 
outcome data on a total of 100,869 lung cancer cases managed within 
the time frame of 1990-2000. Of the 67,725 NSCLC that met the initial 
screening requirements of a complete set of TNM by either clinical or 
pathological staging, known histological type, and survival follow-up, 
38,265 cases with no clinical evidence of metastatic disease (cM0) had 
information on clinical N staging (cN) and 28,371 surgically managed 
patients provided information on pathologic N staging (pN). Further 
analyses of overall survival in relationship to subsets of pN1 and pN2 
stages were performed on 2,876 cases that underwent R0 (microscopi-
cally complete) resection without induction therapy and that success-
fully met logic checks of pN stage for data accuracy.
Surgical cases form Japan were staged according to the Naruke lymph 
node map, adopted by the Japan Lung Cancer Society as the ofﬁcial 
staging map2, while those from all other countries were staged accord-
ing to the Mountain-Dresler modiﬁcation of the American Thoracic 
society (MD-ATS) map.3 Survival was measured from the date of entry 
(date of diagnosis for registries, date of registration for protocols) for 
clinically staged data and the date of surgery for pathologically staged 
data, and was calculated by the Kaplan-Meier method. Prognostic 
groups were assessed by Cox regression analysis.
The overall survival by cN staging for all 38,265 cM0 (any T stage) 
showed clear differences in outcome for each of the cN categories. 
The overall survival by pN staging for the 28,371 cM0 (any T stage) 
patients who were managed surgically (and also had no evidence of in-
trathoracic M1 disease at thoracotomy) again showed signiﬁcant differ-
ences in outcome for each of the pN categories. Exploratory analyses 
were performed to determine if, in patients with pN staging, survival 
was inﬂuenced by the anatomical location of involved lymph nodes, by 
the presence of “skip metastases” (N2 disease in the absence of N1), or 
by the number of involved lymph node stations. No signiﬁcance differ-
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ences in survival could be identiﬁed apart from the general ﬁnding that 
survivorship decreased as the number of positive stations increased.
In order to reconcile the Naruke and MD-ATS lymph node maps and 
permit analyses of cases with N1 and especially N2 disease to include 
larger number of patients, lymph node stations were grouped together 
into anatomical “zones”. Lymph nodes at levels 1-4 were grouped to-
gether into the “upper zone”, levels 5 and 6 into the “AP zone”, level 7 
into the “subcarinal zone”, levels 8 and 9 into the “lower zone”, levels 
10 and 11 into the “hilar zone”, and levels 12-14 into the “peripheral 
zone”. The appropriateness of grouping lymph node stations into 
“zones” was suggested by exploratory analyses that failed to identify 
signiﬁcant differences in survival in relationship to disease in all of the 
various N1 and N2 lymph node stations in data submitted from Japan, 
or from non-Japanese groups, or both. Signiﬁcant differences in sur-
vival for patients with lymph node metastases conﬁned to a single zone 
were only seen for cases of right-sided tumors with upper or subcarinal 
zone disease compared to peripheral zone metastases. No differences 
in survival were identiﬁed among patients who had single zone N2 
disease. AP zone disease in the absence of N1 metastases was associ-
ated with a better survival in patients with left upper tumors, but similar 
differences in survival were not identiﬁed for right upper lobe tumors 
with right paratracheal nodal metastases.
The potential impact of the number of involved lymph node zones 
on survival was then examined. Three groups were found to have 
signiﬁcantly different survivals: patients who had N1 single zone 
disease, those who had either multiple N1 or single N2 zone metastases 
and those who had multiple N2 lymph node zones involved. These 
prognostically distinct groups suggested that it might be appropriate to 
subdivide the current N staging descriptors into N1a (single N1 zone), 
N1b (multiple N1 zones), N2a (single N2 zones), and N2b (multiple 
N2 zones). In order to determine whether such a revision to the staging 
system should be considered, these additional N categories were ana-
lyzed in conjunction with each T stage category (e.g. T1N1a, T1N1b, 
T1N2a, T1N2b, etc.) rather than across all T stages as was done for all 
of the preceding analyses. However, the number of patients available in 
each of these subsets was too small to yield statistically valid analyses. 
Therefore, on the basis of the available data, we cannot recommend 
altering the current N stage descriptors.
In summary, analyses of clinical and pathological N staging in the 
IASLC database support the continued use of the current N descriptors 
in the lung cancer database. Additional analyses suggest that consolida-
tion of multiple lymph node stations into “zones” and stratiﬁcation of 
patients into 3 groups according to the extent of nodal disease may be 
appropriate and warrant inclusion in future studies.
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Purpose: To analyse all non-lymphatic metastatic components (T4 and 
M1) of the current TNM system of lung cancer with the objective of 
providing suggestions for the next edition of the TNM classiﬁcation for 
lung cancer.
Material and Methods: Data on 100,809 patients were submitted to 
the International Association for the Study of Lung Cancer Interna-
tional Database. 5,592 selected T4M0 and M1 patients fulﬁlled the in-
clusion criteria for the analysis. Speciﬁc categories of clinically staged 
T4 (lesions not continuous with the primary tumor) and M1 cases were 
compared with respect to overall survival using Kaplan-Meier survival 
estimates and comparisons via Cox regression analysis. Relevant ﬁnd-
ings were internally validated by geographic area and type of database, 
and externally validated by the North-American Surveillance, Epidemi-
ology and End Results Registries. 
Results: Median survival for cT4M0 with malignant pleural effusion 
was signiﬁcantly worse than that of other cT4M0 patients (8 months vs. 
13 months) and was more comparable to M1 cases with metastases to 
the lung only (10 months). M1 cases with metastases outside the lung/
pleura had a signiﬁcantly poorer prognosis than those with metastases 
conﬁned to the lung, with a median survival of 6 months.
Conclusions: Revisions to the TNM classiﬁcation system for lung 
cancer should include grouping cases with malignant pleural effusions 
and cases with nodules in the contralateral lung in the M1a category, 
and cases with distant metastases should be designated M1b. In addi-
tion, cases with nodule(s) in the ipsilateral lung (non-primary lobe), 
currently staged M1, should be reclassiﬁed as T4M0, in accordance 
with the recommendations of T descriptor sub-committee of the IASLC 
International Staging committee.
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Potential a priori useful prognostic variables for survival of patients 
presenting with lung cancer, as determined according to the series anal-
yses reported in the literature, include in addition to the TNM stage:
• Tumour characteristics : localization of metastatic sites : brain, liver, 
adrenals, bone, lung; number of metastatic sites; pleural effusion; 
type of lesions (assessable, measurable); tumour size and volume; 
histology : non-small cell lung cancer (NSCLC) or small cell lung 
cancer (SCLC); squamous cell carcinoma versus adenocarcinoma 
versus large cell carcinoma ...; neuroendocrine tumours; tumour 
differentiation and grade ; lymphatic and blood vessel invasion; 
symptoms; ﬂuorodeoxyglucose positron emission tomography 
(FDG-PET) scan
• Patients characteristics : age; sex; performance status (PS); weight 
loss; smoking history; race; comorbidities (Charslon’s index, 
Colinet’s simpliﬁed comorbidity score)
• Laboratory parameters : serum bilirubin; serum calcium ; serum 
sodium ; serum creatinine; haemoglobinemia; leucocytosis; neutro-
